FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry and specifically to a compound selected from said compounds or a pharmaceutically acceptable salt thereof. Also disclosed are a pharmaceutical composition for inhibiting the activity of BTK or a mutant thereof, a method of inhibiting BTK activity or a mutant thereof, a method of treating a BTK mediated disorder, a method of treating lupus and the use of said compounds for preparing a medicament for the preventive or therapeutic treatment of a BTK mediated disorder.
,
,
and
.
EFFECT: technical result is obtaining novel heterocyclic compounds which are BTK inhibitors.
6 cl, 238 dwg, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| HETEROARYL COMPOUNDS AS TKB INHIBITORS AND USE THEREOF | 2015 |
|
RU2742122C2 |
| COMPOUNDS | 2019 |
|
RU2800063C2 |
| PYRIMIDINES AND THEIR OPTIONS, AND THEIR APPLICATION | 2017 |
|
RU2760733C2 |
| HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | 2010 |
|
RU2615130C2 |
| PYRIDINES, PYRIMIDINES AND PYRAZINES AS BRUTON'S TYROSINE KINASE INHIBITORS AND USE THEREOF | 2014 |
|
RU2712220C2 |
| HETEROARYL-SUBSTITUTED PYRAZOLE-PYRIDINE PROTEIN KINASE INHIBITORS FOR STIMULATING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH | 2020 |
|
RU2837173C2 |
| PYRAZOLE COMPOUNDS AS MODULATORS OF FSHR AND USES THEREOF | 2014 |
|
RU2663898C2 |
| PROTEIN-TYROSINPHOSPHATASE INHIBITORS AND METHODS OF THEIR USE | 2019 |
|
RU2799446C2 |
| HPK1 INHIBITORS AND USE THEREOF | 2020 |
|
RU2839132C2 |
| MODULATION OF CHEMOSENSORY RECEPTORS AND ASSOCIATED LIGANDS | 2008 |
|
RU2586282C2 |
